Item 1.01. Entry into a Material Definitive Agreement.

On January 4, 2023, SomaLogic Operating Co., Inc. ("SomaLogic OpCo"), a wholly-owned subsidiary of SomaLogic, Inc. (the "Company"), entered into Amendment #2 to Master Collaboration Agreement (the "Amendment") with Novartis Pharma AG ("Novartis"). The Amendment amends the Master Collaboration Agreement, dated as of September 20, 2019, by and between SomaLogic OpCo and Novartis, as amended by the First Amendment, dated June 15, 2021 (collectively, the "Collaboration Agreement"), pursuant to which the parties engage in collaborative research efforts to advance the study of proteomic medicine and SomaLogic OpCo provides SomaScan® assay services to Novartis.

The Amendment modifies the Collaboration Agreement, among other ways, as follows:

? It extends the term of the Collaboration Agreement for the Company to remain

Novartis' primary proteomics platform provider through December 31, 2033.

? The Amendment permits all data generated from samples submitted after the

satisfaction of all Projected Annual Minimums (as defined in the Collaboration

Agreement) due on December 31, 2022 (the "Satisfaction Date") to be disclosed

and sublicensed by Novartis to any Novartis Collaboration Partner (as defined

in the Collaboration Agreement) without any additional obligation to SomaLogic

OpCo.

? For services performed after the Satisfaction Date, it increases the fees

Novartis and its affiliates pay for samples provided by the Company and

specifies that Novartis will provide SomaLogic OpCo with rolling, non-binding

forecasts of its assay requirements on a quarterly basis.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the actual text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.





Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements, which statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current plans, estimates, and expectations, and are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. The risks and uncertainties that may affect the Company's future results of operations are identified and described in more detail in its filings with the Securities and Exchange Commission. You should not place undue reliance on the forward-looking statements contained herein, which speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update these statements as a result of new information or future events.

Item 9.01. Financial Statements and Exhibits.





Exhibit
Number    Exhibit Description
10.1        Amendment No. 2 to Master Collaboration Agreement, dated as of January
          4, 2023, by and between SomaLogic Operating Co., Inc. and Novartis
          Pharma AG.
104       Cover Page Interactive Data File (embedded within the Inline XBRL
          document)




                                       1

© Edgar Online, source Glimpses